Starpharma will be hosting investor conference calls to discuss results of the Company’s phase 3 clinical trial for the treatment of bacterial vaginosis.  The calls will be hosted by Starpharma Chief Executive Officer Dr Jackie Fairley.

Starpharma today announced the results of its two phase 3 studies of VivaGel^® for the treatment of bacterial vaginosis (BV).  Both studies showed that VivaGel^® achieved statistically significant Clinical Cure and resolution of patient-reported symptoms of BV at the End of Treatment visit (EOT, 2-5 days post treatment).  However, the primary endpoint of Clinical Cure 2-3 weeks after the cessation of treatment (Test of Cure, TOC visit) was not met. 

Starpharma  today announced that following a submission to AusIndustry, it is eligible to receive approximately $6 million cash in R&D tax incentive for overseas R&D activities.

The Herald Sun’s Chief Business Writer John Beveridge reported on Starpharma’s announcement that a breast cancer study in mice which showed that adding dendrimers to the chemotherapy drug docetaxel led to drug concentrations within tumours of more than 40 times compared to using the drug alone.

John also profiles the technology platform – “Starpharma has built three exceptional opportunities, all of which promise significant revenue…” The sleeper in the Starpharma portfolio is using dendrimers to improve a range of agricultural chemicals, starting with the herbicide glyphosate.

Starpharma will today present at the Bell Potter LifeScience Conference for professional and sophisticated investors.

The conference is expected to be attended by more than 150 people including the leading institutional investors, high net-worth investors, and other influential industry players.

Starpharma was last night named the industry’s 2012 Australian Company of the Year.

The Janssen 2012 Industry Excellence Awards were announced in Melbourne at Australia’s largest industry conference AusBiotech 2012, where Starpharma was awarded the top honour.

Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 September 2012

 Starpharma today announced that its new agrochemical dendrimer formulations have shown further improved features compared to commercially available products.

Respected Criterion columnist for The Australian Tim Boreham reported on promising results from Starpharma’s latest studies to improve leading cancer drug docetaxel, with its proprietary dendrimer technology. He also commented on Starpharma’s very promising VivaGel portfolio.

Starpharma today reported significant tumour-targeting results with its proprietary dendrimer-docetaxel formulation.